secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2023-04-12T23:59:59+00:00
Accession:  0001193125-23-098423
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum reports preliminary Q1 2023 revenue of $31.5M, cash $232.1M; updates VISTAS trial timeline
--------------------------------------------------------------------------------

- Preliminary Q1 2023 total revenue ~$31.5M, product sales net ~$29M, license revenue ~$2.5M.
- Cash, cash equivalents and short-term investments ~$232.1M as of March 31, 2023.
- Operating expenses consistent to moderately increased versus Q4 2022.
- VISTAS Phase 2b (volixibat in PSC) blinded interim analysis now expected H2 2023.
- VANTAGE Phase 2b (PBC) interim and EMBARK Phase 2b (biliary atresia) topline data remain on track for H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000119312523098423/0001193125-23-098423-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000119312523098423/d442377d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-098423

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer